Uncategorized
International Study Shows 3-Year Benefits of Glaukos iStent® Trabecular Micro-Bypass Stent in Combination with Cataract Surgery
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international clinical study, published in the Journal of Cataract and Refractive Surgery, showed use of the iStent® Trabecular Micro-Bypass Stent in conjunction with cataract surgery provided a 36% reduction in mean int
